Daiwa SB Investments Ltd. Has $176,000 Position in Humana Inc (HUM)
Daiwa SB Investments Ltd. boosted its position in shares of Humana Inc (NYSE:HUM) by 44.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 710 shares of the insurance provider’s stock after purchasing an additional 220 shares during the period. Daiwa SB Investments Ltd.’s holdings in Humana were worth $176,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of the stock. WFG Advisors LP boosted its position in Humana by 4.5% in the 2nd quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after buying an additional 20 shares during the period. Fieldpoint Private Securities LLC purchased a new stake in Humana in the 3rd quarter valued at about $115,000. Acrospire Investment Management LLC purchased a new stake in Humana in the 2nd quarter valued at about $120,000. Northwestern Mutual Wealth Management Co. boosted its position in Humana by 139.5% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock valued at $134,000 after buying an additional 325 shares during the period. Finally, ClariVest Asset Management LLC purchased a new stake in Humana in the 3rd quarter valued at about $144,000. Institutional investors own 94.01% of the company’s stock.
Shares of Humana Inc (HUM) opened at $268.02 on Friday. Humana Inc has a 52-week low of $186.25 and a 52-week high of $271.99. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.61 and a current ratio of 1.61. The company has a market cap of $37,887.92, a P/E ratio of 22.63, a P/E/G ratio of 1.73 and a beta of 0.88.
Humana declared that its Board of Directors has initiated a share buyback plan on Thursday, December 14th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a yield of 0.60%. Humana’s payout ratio is 12.59%.
In other Humana news, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the transaction, the senior vice president now owns 11,704 shares in the company, valued at approximately $2,901,304.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Brian P. Leclaire sold 1,679 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the transaction, the senior vice president now owns 9,888 shares in the company, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. Insiders have sold a total of 10,115 shares of company stock worth $2,501,627 in the last 90 days. 0.80% of the stock is currently owned by company insiders.
HUM has been the subject of several research reports. Credit Suisse Group lowered their price objective on shares of Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. BMO Capital Markets initiated coverage on shares of Humana in a research report on Monday, October 16th. They issued an “outperform” rating and a $300.00 price objective for the company. Goldman Sachs Group began coverage on shares of Humana in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $305.00 price objective for the company. Finally, Zacks Investment Research cut shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Ten equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Humana presently has an average rating of “Buy” and a consensus price target of $258.90.
ILLEGAL ACTIVITY WARNING: “Daiwa SB Investments Ltd. Has $176,000 Position in Humana Inc (HUM)” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/daiwa-sb-investments-ltd-has-176000-position-in-humana-inc-hum/1805639.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.